Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: Immunomedics, Inc
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 5 ans
A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia
The primary objective is to evaluate the efficacy of epratuzumab in WM as determined by the response rate for patients with partial or complete responses.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 5 ans
A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia
To determine if a subcutaneous dosing schedule of veltuzumab can be established in NHL or CLL paitent and to confirm safety and efficacy of veltuzumab that was previously established when administered...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 5 ans
A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer
To evaluate the feasibility, safety and tolerability of this treatment regimen, and to determine acceptable 90-Y dose and gemcitabine dosing for use with this approach.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 5 ans
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus
The primary study objective is to demonstrate that epratuzumab is effective for improvement of the signs and symptoms of SLE.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 5 ans
Estudio en fase III, multicéntrico, doble-ciego, aleatorizado, controlado con placebo de Epratuzumab en pacientes con crisis agudas severas de Lupus Eritematoso Sistémico excluyendo los sistemas renal o neurológico
El objetivo principal del estudio es demostrar que epratuzumab es eficaz para el tratamiento de la exacerbación aguda de lupus.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Immunomedics, Inc
Update Il y a 5 ans
Radioimmunotherapy with 90Y-Clivatizumab Tetraxetan plus Low Dose Gemcitabine versus Placebo plus Low-Dose Gemcitabine
Overall Survival (OS)
Country
None
organs
None
Specialty
None
Closed trial
More information